NR4A1 and glycogen storage disease VI: In a planned exploratory analysis of the TNBC subgroup of patients, a significant clinical benefit was observed in DFS after 26.1 months of follow-up (p = 0.013), in contrast to patients with hormone-receptor positive, node-positive and node-negative diseases, with which the vaccine proved to have no significant clinical benefit [34,36].